Evolution of direct costs in the first years of rheumatoid arthritis: impact of early versus late biologic initiation – an economic analysis based on the espoir cohort

HIGHLIGHTS

• who: ESPOIR Cohort and collaborators from the France, and Curie University (UPMC), Paris, UPMC GRC, Institut Louis d'Epidémiologie et Santé Publique, Paris, France, Pharmacology and have published the article: Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort, in the Journal: PLOS ONE | www.plosone.org of December/11,/2013
• what: The study reported the costs of a large sample of EA patients, more than 80% of whom satisfied the RA classification criteria. [13,31,32 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.